데스모이드 종양 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the desmoid tumors market is projected to be USD 3.02 billion in 2025, USD 3.20 billion in 2026, and reach USD 4.51 billion by 2031, growing at a CAGR of 7.13% from 2026 to 2031.

This report is Segmented by Treatment Type (Targeted Therapy, Radiation Therapy, Chemotherapy, and More), Tumor Type and Location (Abdominal Wall Desmoid Tumors, Intra-Abdominal Desmoid Tumors, and More), End-User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Desmoid Tumors Market Trends and Insights

Rising Diagnosis of Rare Soft Tissue Tumors

Improved diagnostic specificity is bringing more patients into formal treatment pathways in the desmoid tumors market, instead of leaving them grouped under broad fibrous lesion labels. The Desmoid Tumour Working Group recommends routine CTNNB1 mutational analysis on biopsy samples to confirm the diagnosis and guide management, and this standard is spreading across major cancer centers in North America and Europe. Wider use of next-generation sequencing panels in soft tissue tumor clinics is also helping clinicians identify cases that were once labeled as nonspecific fibromatoses, even when the true incidence does not change. For the desmoid tumors market, this means the diagnosed pool can expand even in a rare disease setting where patient numbers remain naturally constrained.

Expanding Clinical Pipeline for Targeted Therapies

The desmoid tumors market in 2026 has its most active targeted therapy pipeline so far, with one approved oral gamma secretase inhibitor, a second late-stage oral agent, and several earlier programs using different Wnt and B-catenin approaches. Immunome reported that varegacestat delivered a 56% objective response rate versus 9% for placebo in the Phase 3 RINGSIDE trial, along with a median tumor volume reduction of 83%, which supported the NDA submission in April 2026 and FDA acceptance in July 2026.Those results were also presented at the 2026 ASCO Annual Meeting, which raised prescriber awareness before any approval decision in 2027. As more products enter the field, the desmoid tumors market is likely to gain from higher physician attention, better case finding, and broader treatment discussion beyond specialist sarcoma networks.

High Treatment Cost and Reimbursement Friction

High orphan drug pricing remains a direct limit on patient access in the desmoid tumors market, especially outside the few countries with strong rare disease reimbursement systems. In the United States, Medicare Part D reforms that took effect in 2025 capped annual out-of-pocket drug spending at USD 2,000 and removed the coverage gap, which improved access for eligible patients using high-cost therapies. The same kind of support is still weaker or absent in many growth markets, including Brazil, Gulf healthcare systems, and India, which leaves access divided between well-funded specialist settings and everyone else. Prior authorization through specialty pharmacy channels also slows uptake because it adds paperwork, multi-week review periods, and appeals that many general oncology practices do not want to manage. This keeps prescribing concentrated in a small set of expert centers and limits how fast the desmoid tumors market can widen beyond established referral networks.

Other drivers and restraints analyzed in the detailed report include:

1. Broader Use of Oral, Non-Surgical Treatment Pathways
2. Genetic Profiling and Mutation-Guided Therapy Selection
3. Active Surveillance Reducing Immediate Drug Demand

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Targeted therapy held 41.23% share of the desmoid tumors market size in 2025, which made it the leading treatment category after years in which the field had no approved systemic option. Nirogacestat remains the commercial anchor, and 4-year follow-up from the DeFi Phase 3 trial showed the objective response rate rising from 34.3% at year 1 to 45.7% after 4 years of continuous treatment, with a median best tumor size reduction of 75.8% among long-term completers. It also helps explain why targeted therapy is becoming the reference standard across much of the desmoid tumors industry, even though watchful waiting still remains important for selected patients.

Chemotherapy is expected to be the fastest-growing treatment category, with the desmoid tumors market for this segment expected to expand at an 8.84% CAGR through 2031. This does not suggest a return to older practice patterns, but it does show that metronomic regimens such as methotrexate plus vinblastine still meet a real need in pediatric cases, lower-resource settings, and periods when patients are waiting for access to newer drugs. Radiation therapy, cryoablation, radiofrequency ablation, and embolization remain part of the broader toolkit, which means the desmoid tumors market continues to reflect a mixed treatment structure rather than a single-pathway model.

Complete Report Scope:

• By Treatment Type
  • Targeted Therapy
  • Radiation Therapy
  • Chemotherapy
  • Other Treatment Types
• By Tumor Type and Location
  • Abdominal Wall Desmoid Tumors
  • Intra-Abdominal Desmoid Tumors
  • Extra-Abdominal Desmoid Tumors
  • Head and Neck Desmoid Tumors
  • Thoracic and Chest Wall Desmoid Tumors
• By End-User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 46.22% of the desmoid tumors market in 2025, and the region remains the main commercial center because the United States already has an approved systemic therapy and a functioning specialty pharmacy support structure. The U.S. also had 10,000 to 11,000 patients under active management in 2026, which gives the region the largest treated patient pool and the most established payer environment for orphan oncology products. Canada still has a slower commercial path while Mexico faces affordability limits because it lacks an orphan reimbursement structure comparable to the United States.

Europe remained the second-largest regional block in the desmoid tumors market in 2025, and the most important recent event was the European Commission approval of Ogsiveo in August 2025 as the first and only approved therapy in the region. Germany looks well placed for early uptake because of its specialist sarcoma infrastructure and the weight of clinical leadership involved in the DeFi development program. The joint assessment approach under the EU HTA framework could help streamline evaluation for orphan oncology products across member states once national pricing discussions begin. The UK remains on a separate track through MHRA and NICE review, which extends the time needed for full commercial rollout compared with the EU approval path.

Asia-Pacific is projected to be the fastest-growing regional area, with the desmoid tumors market expected to rise at a 9.44% CAGR through 2031. Japan stands out because its National Cancer Center listed nirogacestat in 2025 as an unapproved drug with high medical necessity, which points to a clearer regulatory path than many other regional markets. China is building relevance through growing academic experience and new investigational activity, including the April 2026 launch of the ES014 Phase 2 study. Australia, South Korea, and India are also becoming more relevant as oncology infrastructure, rare disease awareness, and insurance support improve, but the region still starts from lower penetration than North America or Western Europe. South America and the Middle East and Africa remain longer-term opportunities, with the Gulf states supported by hospital investment and Brazil and Argentina providing a narrower base through public systems and academic oncology centers.

1. Amgen
2. Apollomics Inc.
3. AstraZeneca
4. Ayala Pharmaceuticals, Inc.
5. Bayer
6. Bristol-Myers Squibb
7. Eisai
8. Eli Lilly and Company
9. Immunome, Inc.
10. Ipsen
11. Iterion Therapeutics, Inc.
12. Johnson & Johnson
13. Merck
14. Novartis
15. Parabilis Medicines
16. Pfizer
17. PRISM BioLab Co., Ltd.
18. Roche
19. SpringWorks Therapeutics, Inc.
20. Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diagnosis of Rare Soft Tissue Tumors
  • 4.2.2 Expanding Clinical Pipeline for Targeted Therapies
  • 4.2.3 Broader Use of Oral, Non-Surgical Treatment Pathways
  • 4.2.4 Genetic Profiling and Mutation-Guided Therapy Selection
  • 4.2.5 Rare Disease Registries Improving Case Identification and Referral
  • 4.2.6 Expanded Payer Acceptance for Orphan-Drug Innovation
• 4.3 Market Restraints
  • 4.3.1 Limited Number of Approved Therapies
  • 4.3.2 High Treatment Cost and Reimbursement Friction
  • 4.3.3 Active Surveillance Reducing Immediate Drug Demand
  • 4.3.4 Clinical Heterogeneity and Small Patient Pool
• 4.4 Supply/Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment Type
  • 5.1.1 Targeted Therapy
  • 5.1.2 Radiation Therapy
  • 5.1.3 Chemotherapy
  • 5.1.4 Other Treatment Types
• 5.2 By Tumor Type and Location
  • 5.2.1 Abdominal Wall Desmoid Tumors
  • 5.2.2 Intra-Abdominal Desmoid Tumors
  • 5.2.3 Extra-Abdominal Desmoid Tumors
  • 5.2.4 Head and Neck Desmoid Tumors
  • 5.2.5 Thoracic and Chest Wall Desmoid Tumors
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Clinics
  • 5.3.3 Ambulatory Surgical Centers
  • 5.3.4 Other End-Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Amgen Inc.
  • 6.3.2 Apollomics Inc.
  • 6.3.3 AstraZeneca PLC
  • 6.3.4 Ayala Pharmaceuticals, Inc.
  • 6.3.5 Bayer AG
  • 6.3.6 Bristol-Myers Squibb Company
  • 6.3.7 Eisai Co., Ltd.
  • 6.3.8 Eli Lilly and Company
  • 6.3.9 Immunome, Inc.
  • 6.3.10 Ipsen S.A.
  • 6.3.11 Iterion Therapeutics, Inc.
  • 6.3.12 Johnson and Johnson
  • 6.3.13 Merck KGaA
  • 6.3.14 Novartis AG
  • 6.3.15 Parabilis Medicines
  • 6.3.16 Pfizer Inc.
  • 6.3.17 PRISM BioLab Co., Ltd.
  • 6.3.18 Roche Holding AG
  • 6.3.19 SpringWorks Therapeutics, Inc.
  • 6.3.20 Takeda Pharmaceutical Company Limited

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment